CY1109532T1 - Παραγωγα ινδολο 1-οξεικου οξεος με pgd2 ανταγωνιστικη δραστικοτητα - Google Patents
Παραγωγα ινδολο 1-οξεικου οξεος με pgd2 ανταγωνιστικη δραστικοτηταInfo
- Publication number
- CY1109532T1 CY1109532T1 CY20091101280T CY091101280T CY1109532T1 CY 1109532 T1 CY1109532 T1 CY 1109532T1 CY 20091101280 T CY20091101280 T CY 20091101280T CY 091101280 T CY091101280 T CY 091101280T CY 1109532 T1 CY1109532 T1 CY 1109532T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pgd2
- indole
- competitive activity
- alkyl
- acid producers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Ενώσεις του γενικού τύπου (I) όπου R1 είναι αλογόνο ή κυανό, το R2 είναι C1-C4 αλκυλ, και το R3 είναι φαινυλ υποκατεστημένο με έναν ή περισσότερους υποκαταστάτες που επιλέγονται από C1-C6 αλκυλ, αλογόνο ή -SO2(C1-C6 αλκυλ), ή φαρμακευτικά αποδεκτό άλας, υδρίτης, διάλυμα, σύμπλοκο ή προφάρμακο αυτών. Είναι χρήσιμες στην θεραπεία ασθενειών και καταστάσεων που προκαλούνται από την δράση της PGD2 στο CRTH2 υποδοχέα.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0505048.9A GB0505048D0 (en) | 2005-03-11 | 2005-03-11 | Compounds with PGD antagonist activity |
| EP06726357A EP1856045B1 (en) | 2005-03-11 | 2006-03-10 | 1-acetic acid-indole derivatives with pgd2 antagonist activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1109532T1 true CY1109532T1 (el) | 2014-08-13 |
Family
ID=34508918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091101280T CY1109532T1 (el) | 2005-03-11 | 2009-12-08 | Παραγωγα ινδολο 1-οξεικου οξεος με pgd2 ανταγωνιστικη δραστικοτητα |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8044088B2 (el) |
| EP (1) | EP1856045B1 (el) |
| JP (1) | JP2008532990A (el) |
| KR (1) | KR20070116633A (el) |
| CN (1) | CN101166721A (el) |
| AT (1) | ATE442356T1 (el) |
| AU (1) | AU2006221784A1 (el) |
| BR (1) | BRPI0608732A2 (el) |
| CA (1) | CA2601980A1 (el) |
| CY (1) | CY1109532T1 (el) |
| DE (1) | DE602006009080D1 (el) |
| DK (1) | DK1856045T3 (el) |
| ES (1) | ES2333161T3 (el) |
| GB (1) | GB0505048D0 (el) |
| HK (1) | HK1109628A1 (el) |
| HR (1) | HRP20090654T1 (el) |
| IL (1) | IL185844A0 (el) |
| MX (1) | MX2007011091A (el) |
| NO (1) | NO20074641L (el) |
| NZ (1) | NZ561747A (el) |
| PL (1) | PL1856045T3 (el) |
| PT (1) | PT1856045E (el) |
| RS (1) | RS51016B (el) |
| RU (1) | RU2007134456A (el) |
| SI (1) | SI1856045T1 (el) |
| WO (1) | WO2006095183A1 (el) |
| ZA (1) | ZA200708159B (el) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| EP2037967B1 (en) | 2006-06-16 | 2016-12-07 | The Trustees Of The University Of Pennsylvania | Prostaglandin d2 receptor antagonists for treating androgenetic alopecia |
| DK2046740T3 (da) | 2006-07-22 | 2012-08-20 | Oxagen Ltd | Forbindelser med CRTH2-antagonistisk virkning |
| SI2051962T1 (sl) | 2006-08-07 | 2012-02-29 | Actelion Pharmaceuticals Ltd | Derivati (3-amino-1,2,3,4-tetrahidro-9h-karbazol-9-il)-ocetne kisline |
| GB0722203D0 (en) * | 2007-11-13 | 2007-12-19 | Oxagen Ltd | Use of CRTH2 antagonist compounds |
| GB0722216D0 (en) * | 2007-11-13 | 2007-12-27 | Oxagen Ltd | Use of crth2 antagonist compounds |
| PT2327693E (pt) * | 2007-12-14 | 2012-07-24 | Pulmagen Therapeutics Asthma Ltd | Indoles e sua utilização terapêutica |
| WO2009090414A1 (en) * | 2008-01-18 | 2009-07-23 | Oxagen Limited | Compounds having crth2 antagonist activity |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| EP2240444A1 (en) * | 2008-01-22 | 2010-10-20 | Oxagen Limited | Compounds having crth2 antagonist activity |
| US8470594B2 (en) * | 2008-04-15 | 2013-06-25 | President And Fellows Of Harvard College | Methods for identifying agents that affect the survival of motor neurons |
| US9180114B2 (en) | 2008-11-26 | 2015-11-10 | President And Fellows Of Harvard College | Neurodegenerative diseases and methods of modeling |
| UA105039C2 (uk) * | 2009-02-24 | 2014-04-10 | Мерк Шарп Енд Доме Корп. | Похідні індолу як антагоністи рецептора crth2 |
| KR101444572B1 (ko) | 2010-03-22 | 2014-09-24 | 액테리온 파마슈티칼 리미티드 | 3-(헤테로아릴-아미노)-1,2,3,4-테트라히드로-9ｈ-카르바졸 유도체 및 이의 프로스타글란딘 ｄ2 수용체 조절제로서의 용도 |
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| ES2596581T3 (es) | 2011-04-14 | 2017-01-10 | Actelion Pharmaceuticals Ltd. | Derivados de ácido 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indol acético y su uso como moduladores del receptor de prostaglandina D2 |
| SI2781508T1 (sl) * | 2011-11-17 | 2019-03-29 | Kbp Biosciences Co., Ltd. | Zlite obročne spojine, ki vsebujejo dušik za uporabo kot antagonisti CRTH2 |
| GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| US20140328861A1 (en) | 2011-12-16 | 2014-11-06 | Atopix Therapeutics Limited | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis |
| US9797903B2 (en) | 2012-10-24 | 2017-10-24 | Winthrop-University Hospital | Non-invasive biomarker to identify subject at risk of preterm delivery |
| KR102116978B1 (ko) | 2013-10-07 | 2020-05-29 | 삼성전자 주식회사 | 그래핀 소자 및 그 제조 방법 |
| GB201322273D0 (en) * | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
| MY179356A (en) | 2014-03-17 | 2020-11-05 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| GB201407807D0 (en) * | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| KR20180031019A (ko) | 2015-07-30 | 2018-03-27 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Ｐｇｄ２에 의한 모발 성장 억제에 대한 민감성의 검출을 위한 인간 ｄｐ―２ 유전자의 단일 뉴클레오티드 다형성 대립유전자 |
| TWI711616B (zh) | 2015-09-15 | 2020-12-01 | 瑞士商愛杜西亞製藥有限公司 | 結晶型式 |
| AU2018331400A1 (en) | 2017-09-13 | 2020-04-02 | Progenity, Inc. | Preeclampsia biomarkers and related systems and methods |
| CN109180691B (zh) * | 2018-08-24 | 2020-07-10 | 武汉大学 | 一种c3-芳香型吡咯并吲哚类生物碱及其合成方法 |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
| CN113425714B (zh) * | 2021-08-04 | 2022-04-26 | 华南师范大学 | 吲哚乙酸在制备防治慢性阻塞性肺病药物中的应用 |
| CN114870018A (zh) * | 2022-05-12 | 2022-08-09 | 江南大学 | 炎症小体nlrp3抑制剂通过抑制神经系统炎症在制备治疗阿尔茨海默症药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641800A (en) * | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
| YU59600A (sh) * | 1998-03-31 | 2002-12-10 | The Institute For Pharmaceutical Discovery Inc. | Supstituisane indolalkanoidske kiseline |
| US7534897B2 (en) * | 2002-05-16 | 2009-05-19 | Shionogi & Co., Ltd. | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism |
| TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) * | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| SE0302232D0 (sv) * | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| GB0504150D0 (en) * | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
| DK2046740T3 (da) * | 2006-07-22 | 2012-08-20 | Oxagen Ltd | Forbindelser med CRTH2-antagonistisk virkning |
| PT2327693E (pt) | 2007-12-14 | 2012-07-24 | Pulmagen Therapeutics Asthma Ltd | Indoles e sua utilização terapêutica |
| US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| JP2011509990A (ja) * | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| EP2240444A1 (en) * | 2008-01-22 | 2010-10-20 | Oxagen Limited | Compounds having crth2 antagonist activity |
-
2005
- 2005-03-11 GB GBGB0505048.9A patent/GB0505048D0/en not_active Ceased
-
2006
- 2006-03-10 ES ES06726357T patent/ES2333161T3/es active Active
- 2006-03-10 US US11/908,401 patent/US8044088B2/en not_active Expired - Fee Related
- 2006-03-10 WO PCT/GB2006/000851 patent/WO2006095183A1/en active Application Filing
- 2006-03-10 BR BRPI0608732A patent/BRPI0608732A2/pt not_active IP Right Cessation
- 2006-03-10 PL PL06726357T patent/PL1856045T3/pl unknown
- 2006-03-10 CA CA002601980A patent/CA2601980A1/en not_active Abandoned
- 2006-03-10 CN CNA2006800139287A patent/CN101166721A/zh active Pending
- 2006-03-10 RS RSP-2009/0534A patent/RS51016B/sr unknown
- 2006-03-10 KR KR1020077023379A patent/KR20070116633A/ko not_active Application Discontinuation
- 2006-03-10 DK DK06726357T patent/DK1856045T3/da active
- 2006-03-10 NZ NZ561747A patent/NZ561747A/xx not_active IP Right Cessation
- 2006-03-10 DE DE602006009080T patent/DE602006009080D1/de active Active
- 2006-03-10 RU RU2007134456/04A patent/RU2007134456A/ru not_active Application Discontinuation
- 2006-03-10 SI SI200630491T patent/SI1856045T1/sl unknown
- 2006-03-10 AU AU2006221784A patent/AU2006221784A1/en not_active Withdrawn
- 2006-03-10 EP EP06726357A patent/EP1856045B1/en active Active
- 2006-03-10 PT PT06726357T patent/PT1856045E/pt unknown
- 2006-03-10 AT AT06726357T patent/ATE442356T1/de active
- 2006-03-10 MX MX2007011091A patent/MX2007011091A/es active IP Right Grant
- 2006-03-10 JP JP2008500270A patent/JP2008532990A/ja active Pending
-
2007
- 2007-09-10 IL IL185844A patent/IL185844A0/en unknown
- 2007-09-12 NO NO20074641A patent/NO20074641L/no not_active Application Discontinuation
- 2007-09-21 ZA ZA200708159A patent/ZA200708159B/xx unknown
-
2008
- 2008-04-08 HK HK08103897.0A patent/HK1109628A1/xx not_active IP Right Cessation
-
2009
- 2009-12-08 CY CY20091101280T patent/CY1109532T1/el unknown
- 2009-12-09 HR HR20090654T patent/HRP20090654T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200708159B (en) | 2009-11-25 |
| AU2006221784A1 (en) | 2006-09-14 |
| IL185844A0 (en) | 2008-01-06 |
| HRP20090654T1 (hr) | 2010-01-31 |
| RS51016B (sr) | 2010-10-31 |
| RU2007134456A (ru) | 2009-04-20 |
| EP1856045B1 (en) | 2009-09-09 |
| US8044088B2 (en) | 2011-10-25 |
| MX2007011091A (es) | 2007-11-22 |
| PT1856045E (pt) | 2009-12-09 |
| NZ561747A (en) | 2010-03-26 |
| BRPI0608732A2 (pt) | 2016-11-08 |
| HK1109628A1 (en) | 2008-06-13 |
| US20100330077A1 (en) | 2010-12-30 |
| ATE442356T1 (de) | 2009-09-15 |
| SI1856045T1 (sl) | 2010-01-29 |
| DE602006009080D1 (de) | 2009-10-22 |
| KR20070116633A (ko) | 2007-12-10 |
| JP2008532990A (ja) | 2008-08-21 |
| EP1856045A1 (en) | 2007-11-21 |
| ES2333161T3 (es) | 2010-02-17 |
| GB0505048D0 (en) | 2005-04-20 |
| WO2006095183A1 (en) | 2006-09-14 |
| NO20074641L (no) | 2007-11-01 |
| PL1856045T3 (pl) | 2010-02-26 |
| CN101166721A (zh) | 2008-04-23 |
| DK1856045T3 (da) | 2010-01-04 |
| CA2601980A1 (en) | 2006-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109532T1 (el) | Παραγωγα ινδολο 1-οξεικου οξεος με pgd2 ανταγωνιστικη δραστικοτητα | |
| PE20091005A1 (es) | N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas | |
| GB0510584D0 (en) | Organic compounds | |
| NO20071617L (no) | Indozolonderivater som 11B-HSD1-inhibitorer | |
| ATE388146T1 (de) | 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor | |
| CY1108455T1 (el) | Νεος στεροειδης αγωνιστης δια fxr | |
| TW200640869A (en) | PGD2 receptor antagonists for the treatment of inflammatory diseases | |
| NI200800008A (es) | Métodos para la neuroprotección | |
| NO20091301L (no) | Nye aminopyridinderivater med aurora A selektiv inhiberende aktivitet | |
| NO20083058L (no) | Cykloheksylsulfonamidderivater med H3 reseptor aktivitet | |
| EA200700103A1 (ru) | НОВЫЕ 2-ЗАМЕЩЁННЫЕ D-ГОМО-ЭСТРА-1,3,5(10)-ТРИЕНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 17β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ ТИПА 1 | |
| NO20075734L (no) | Tiofenforbindelser og trombopoietin reseptoractivatorer | |
| BRPI0414738A (pt) | derivados de ácido acético substituìdos | |
| NO20072684L (no) | Konjugater med anti-inflammatorisk aktivitet | |
| DE602006014022D1 (de) | 5-substituierte indol-2-carbonsäureamidderivate | |
| AR076362A1 (es) | Arilsulfonamidas 2,5-disustituidas antagonistas de ccr3, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento y/o prevencion de patologias autoinmunes e inflamatorias, entre otras. | |
| CY1112638T1 (el) | Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον | |
| PE20120217A1 (es) | Derivados de carbamatos de alquil-heterociclos, su preparacion y su aplicacion en terapeutica | |
| CO6321159A2 (es) | Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias | |
| NO20071319L (no) | Fremgangsmate for fremstilling av isotiazolderivater. | |
| NO20080165L (no) | Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister | |
| EA200700871A1 (ru) | Способы нейропротекции | |
| EA201101298A1 (ru) | Аддитивные соли трометамина с производными азабифениламинобензойной кислоты в качестве ингибиторов dhodh | |
| NO20071230L (no) | Oksazolidinoner inneholdende oksindoler som antibakterielle midler | |
| NO20070972L (no) | Benzyloksyderivater som MAOB-inhibitorer |